Skip to main content

Advertisement

SpringerLink
Log in

Efficacy of sorafenib and impact on cardiac function in patients with thyroid cancer: a retrospective analysis

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Purpose

Sorafenib has recently been recognized as an important standard option for the management of patients with differentiated thyroid cancer. Although data concerning cardiac safety are available in pan-tumor studies, no data are available on its use in everyday clinical practice in patients with thyroid cancer.

Methods

In the off-label program of our institution, we enrolled 14 patients with different histological types of thyroid cancer suitable for treatment with sorafenib. Our aims were to evaluate cardiac safety factors—LVEF (left ventricular ejection fraction), heart rate and blood pressure—the cardiac markers NT-proBNP and troponin I, radiological response evaluated by CT and 18FDG-PET (according to RECIST 1.1 criteria) and biomarker reduction (Eastern Cooperative Oncology Group Performance Status: ECOG PS) 0–2.

Results

Patients with ECOG PS 2 accounted for 36 %. After starting sorafenib, many patients displayed reduced or stabilized metabolic activity in target lesions (clinical benefit = 44 %), radiologic reduction or stabilization (74 %) and decreased cancer markers (90 %). Lung metastases displayed the largest reductions in size. Median overall survival (OS) was 7 months and median progression-free survival (PFS) was 3 months. No sign of cardiotoxicity was observed in almost all patients. LVEF was altered in two patients and proved symptomatic in one.

Conclusions

Sorafenib seems to be effective in reducing disease progression in the early stages of treatment (3–6 months). Responses varied considerably according to the criteria investigated. Cardiac toxicities did not raise concerns and were in line with data reported in other malignancies. However, cardiac monitoring is recommended.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Surveillance, epidemiology, and end results program (seer) database 2014 for thyroid cancer. Downloadable at http://seer.cancer.gov/statfacts/html/thyro.html. Accessed 24 Aug 2014

  2. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) (1975–2009) SEER cancer statistics review (vintage 2009 populations), National Cancer Institute, Bethesda

  3. Tuttle MDJ, Pacini F (2014) NCCN guideline: practice guidelines in oncology v 1.2014 J Natl Cancer Inst. Available at www.nccn.org

  4. Puxeddu E, Durante C, Avenia N, Filetti S, Russo D (2008) Clinical implications of BRAF mutation in thyroid carcinoma. Trends Endocrinol Metab 19(4):138–145. doi:10.1016/j.tem.2007.12.003

    Article  PubMed  CAS  Google Scholar 

  5. Pacini F (2012) New insight in the follow-up strategies of differentiated thyroid cancer. J Endocrinol Invest 35(Suppl. to no. 6):36

    PubMed  CAS  Google Scholar 

  6. Tuttle MDJ, Pacini F (2007) NCCN Clinical practice guidelines in oncology thyroid carcinoma V.2.2007 J Natl Cancer Inst. Downloadable at http://www.unifesp.br/dmed/climed/liga/consensos/cancertireoide2007.PDF

  7. Witteles RM, Telli M (2012) Underestimating cardiac toxicity in cancer trials: lessons learned? J Clin Oncol 30(16):1916–1918. doi:10.1200/JCO.2011.40.4012

    Article  PubMed  Google Scholar 

  8. Haraldsdottir S, Shah MH (2014) New era for treatment in differentiated thyroid cancer. Lancet. doi:10.1016/S0140-6736(14)60663-2

    PubMed  Google Scholar 

  9. Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, Hall NC, Wakely PE Jr, Vasko VV, Saji M, Snyder PJ, Wei L, Arbogast D, Collamore M, Wright JJ, Moley JF, Villalona-Calero MA, Shah MH (2010) Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 28(14):2323–2330. doi:10.1200/JCO.2009.25.0068

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  10. Ahmed M, Barbachano Y, Riddell A, Hickey J, Newbold KL, Viros A, Harrington KJ, Marais R, Nutting CM (2011) Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol/Eur Fed Endocr Soc 165(2):315–322. doi:10.1530/EJE-11-0129

    Article  CAS  Google Scholar 

  11. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE Jr, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M, Shah MH (2009) Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27(10):1675–1684. doi:10.1200/JCO.2008.18.2717

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  12. Hoftijzer H, Heemstra KA, Morreau H, Stokkel MP, Corssmit EP, Gelderblom H, Weijers K, Pereira AM, Huijberts M, Kapiteijn E, Romijn JA, Smit JW (2009) Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol/Eur Fed Endocr Soc 161(6):923–931. doi:10.1530/EJE-09-0702

    Article  CAS  Google Scholar 

  13. Schneider TC, Abdulrahman RM, Corssmit EP, Morreau H, Smit JW, Kapiteijn E (2012) Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. Eur J Endocrinol/Eur Fed Endocr Soc 167(5):643–650. doi:10.1530/EJE-12-0405

    Article  CAS  Google Scholar 

  14. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, Sherman SI, Smit JW, Chung J, Kappeler C, Pena C, Molnar I, Schlumberger MJ, On behalf of the Di (2014) Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384(9940):319–328. doi:10.1016/S0140-6736(14)60421-9

    Article  PubMed  CAS  Google Scholar 

  15. Capdevila J, Iglesias L, Halperin I, Segura A, Martinez-Trufero J, Vaz MA, Corral J, Obiols G, Grande E, Grau JJ, Tabernero J (2012) Sorafenib in metastatic thyroid cancer. Endocr Relat Cancer 19(2):209–216. doi:10.1530/ERC-11-0351

    Article  PubMed  CAS  Google Scholar 

  16. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O’Dwyer PJ, Brose MS (2008) Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26(29):4714–4719. doi:10.1200/JCO.2008.16.3279

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  17. Giusti M, Melle G, Fenocchio M, Mortara L, Cecoli F, Caorsi V, Ferone D, Minuto F, Rasore E (2011) Five-year longitudinal evaluation of quality of life in a cohort of patients with differentiated thyroid carcinoma. J Zhejiang Univ Sci B 12(3):163–173. doi:10.1631/jzus.B1000382

    Article  PubMed  PubMed Central  Google Scholar 

  18. Marotta V, Ramundo V, Camera L, Del Prete M, Fonti R, Esposito R, Palmieri G, Salvatore M, Vitale M, Colao A, Faggiano A (2013) Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET. Clin Endocrinol 78(5):760–767. doi:10.1111/cen.12057

    Article  CAS  Google Scholar 

  19. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247. doi:10.1016/j.ejca.2008.10.026

    Article  PubMed  CAS  Google Scholar 

  20. Are C, Shaha AR (2006) Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 13(4):453–464. doi:10.1245/ASO.2006.05.042

    Article  PubMed  Google Scholar 

  21. Hadar T, Mor C, Shvero J, Levy R, Segal K (1993) Anaplastic carcinoma of the thyroid. Eur J Surg Oncol 19(6):511–516

    PubMed  CAS  Google Scholar 

  22. Force T, Krause DS, Van Etten RA (2007) Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7(5):332–344. doi:10.1038/nrc2106

    Article  PubMed  CAS  Google Scholar 

  23. Orphanos GS, Ioannidis GN, Ardavanis AG (2009) Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol 48(7):964–970. doi:10.1080/02841860903229124

    Article  PubMed  CAS  Google Scholar 

  24. Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, Ruhsam M, Hejna M, Schmidinger H (2008) Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 26(32):5204–5212. doi:10.1200/JCO.2007.15.6331

    Article  PubMed  Google Scholar 

  25. Tolcher AW, Appleman LJ, Shapiro GI, Mita AC, Cihon F, Mazzu A, Sundaresan PR (2011) A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemother Pharmacol 67(4):751–764. doi:10.1007/s00280-010-1372-3

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  26. Aaron Benjamin Cohen Mark Yarchoan ABT, Puttaswamy K, Harlacker K, Loevner LA, Brose MS Department of Internal Medicine (2014) Phase II trial of sorafenib in advanced thyroid cancer: A disease site analysis. J Clin Oncol 32 (suppl; abstr e17000)

  27. Cabanillas ME, Sherman SI (2012) Applying new clinicopathological characteristics to prognostication in advanced thyroid carcinoma. Endocr Relat Cancer 19(2):C19–C22. doi:10.1530/ERC-11-0371

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  28. Prior JO, Montemurro M, Orcurto MV, Michielin O, Luthi F, Benhattar J, Guillou L, Elsig V, Stupp R, Delaloye AB, Leyvraz S (2009) Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol 27(3):439–445. doi:10.1200/JCO.2008.17.2742

    Article  PubMed  CAS  Google Scholar 

  29. Vercellino L, Bousquet G, Baillet G, Barre E, Mathieu O, Just PA, Desgrandchamps F, Misset JL, Hindie E, Moretti JL (2009) 18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study. Cancer Biother Radiopharm 24(1):137–144. doi:10.1089/cbr.2008.0527

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

M. Giusti received a research grant from the BAYER pharmaceutical company to perform this study.

Conflict of interest

The authors declare that they have no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Author information

Authors and Affiliations

  1. Endocrine Unit, IRCSS IST-San Martino University Hospital, 16132, Genoa, Italy

    L. Mortara, G. Pera, E. Monti, F. Minuto & M. Giusti

  2. Nuclear Medicine Unit, IRCSS IST-San Martino University Hospital, Genoa, Italy

    S. Morbelli & G. Sambuceti

Authors
  1. L. Mortara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Pera
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Monti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Morbelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F. Minuto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Sambuceti
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Giusti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L. Mortara.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mortara, L., Pera, G., Monti, E. et al. Efficacy of sorafenib and impact on cardiac function in patients with thyroid cancer: a retrospective analysis. J Endocrinol Invest 37, 1099–1108 (2014). https://doi.org/10.1007/s40618-014-0177-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-014-0177-3

Keywords

Search

Navigation